

Express Mail Label No.: EV 312709682 US
Date of Deposit: November 24, 2003

11-26-03
Attorney Docket No.: 24591-501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Becker et al.

SERIAL NUMBER: 10/626,085

EXAMINER: Not Yet Assigned

FILING DATE: July 24, 2003

ART UNIT: Not Yet Assigned

FOR: SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS NEUROKININ ANTAGONISTS

Mail Stop IDS

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of Cited Reference B1-B3; C1-C30; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24591-501. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Matthew Parao Reg No. 50,572

cc:
Ivor R. Elrifi, Reg. No. 39,529
Nicholas P. Triano, III, Reg. No. 36,397
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: November 24, 2003

Date of deposit: November 24, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Becker et al.

SERIAL NUMBER: 10/626,085

EXAMINER: Not Yet Assigned

FILING DATE: July 24, 2003

ART UNIT: Not Yet Assigned

FOR: SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AS NEUROKININ ANTAGONISTS

MAIL STOP IDS

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before receipt of a first Office Action on the merits. Accordingly, no fee is believed due.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT: Becker et al.
U.S.S.N.: 10/626,085

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24591-501.

Respectfully submitted,


Matthew Pavao Reg No 50,572
Ivor R. Elrifi, Reg. No. 39,529
Nicholas P. Triano, III, Reg. No. 36,397
Attorneys for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
Address all written correspondence to
Customer No.: 30623
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: November 24, 2003

TRA 1844992v1

Please type a plus sign (+) in this box

+



Modified Form 1449/PTO

INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	10/626,085
Filing Date	July 24, 2003
First Named Inventor	Becker
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	24591-501

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 93/01160	Merck Sharp & Dohme Limited	01/21/93	
	B2	WO 93/01165	Merck Sharp & Dohme Limited	01/21/93	
	B3	WO 93/01169	Merck Sharp & Dohme Limited	01/21/93	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Goadsby, et al., "Substance P Blockade with the Potent and Centrally Acting Antagonist GR205171 does not Effect Central Trigeminal Activity with Superior Sagittal Sinus Stimulation", <i>Neuroscience</i> , 1998, 86(1):337-343.
	C2	Von Sprecher, et al., "Neurokinin Antagonists as Potential Therapies for Inflammation and Rheumatoid Arthritis", <i>Drugs</i> , 1998, 1(1):73-91.
	C3	Hill, R.G., "Role of Receptors in Nociception", <i>The Tachykinin Receptors</i> , ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 471-498.
	C4	Maggi, et al., "Tachykinin Receptors and Tachykinin Receptor Antagonists", <i>J. Auton. Pharmacol.</i> , 1993, 13(1):23-93.
	C5	Regoli, et al., "Receptors and Antagonists for Substance P and Related Peptides", <i>Pharmacol. Rev.</i> , 1994, 46(4): 551-599.
	C6	Maggio, et al., "History of Tachykinin Peptides", <i>The Tachykinin Receptors</i> ; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 1-21.
	C7	Nakanishi, S., "Mammalian Tachykinin Receptors", <i>Annu. Rev. Neurosci.</i> , 1991, 14:123-136.
	C8	Bellucci, et al., "Pharmacological Profiles of the Novel Mammalian Tachykinin, Hemokinin 1", <i>Br. J. Pharmacol.</i> , 2002, 135(1):266-274.
	C9	Burcher, et al., "Autoradiographic Localization of Receptors in Peripheral Tissues", <i>The Tachykinin Receptors</i> , ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 125-163.
	C10	Krause, et al., "Molecular Biology of Receptors", <i>The Tachykinin Receptors</i> ; ed. S.H. Buck, Humana Press Inc. Totowa, NJ, 1994, 165-218.
	C11	Longmore, et al., "Neurokinin Receptors", <i>Drug News Perspect.</i> 1995, 8 (1):5-23.
	C12	Kucharczyk, N., "Tachykinin Antagonists in Development", <i>Exp. Opin. Invest. Drugs</i> , 1995, 4 (4):299-311.
	C13	Elliott, et al., "Neurokinin Receptor Antagonists", <i>Exp. Opin. Ther. Pat.</i> , 1997, 7 (1):43-54.
	C14	Longmore, et al., "Neurokinin-Receptor Antagonists: Pharmacological Tools and Therapeutic Drugs", <i>Can. J. Physiol. Pharmacol.</i> , 1997, 75:612-621.
	C15	Gerspacher, et al., "Dual Neurokinin NK ₁ /NK ₂ Receptor Antagonists", <i>Drugs Future</i> , 1999, 24(8):883-892.
	C16	Kudlacz, et al., "In Vitro and In Vivo Characterization of MDL 105, 212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonists", <i>J. Pharmacol. Exp. Ther.</i> , 1996, 277(2):840-851.
	C17	Ramsey, et al., "Pharmacological Characterization of ZD6021: A Novel, Orally Active Antagonist of the Tachykinin Receptors", <i>J. Pharmacol. Exp. Ther.</i> , 2001 298(1):307-315.

O I P
 NOV 24 2003
 PATENT & TRADEMARK OFFICE

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam. mited 1845039	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C18	Gerspacher, et al., "N-[(R, R)-(E)-1-(4-Chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3,5-bis-trifluoromethyl-benzamide: An Orally Active Neurikinin NK ₁ /NK ₂ Antagonist", <i>Bioorg. Med. Chem. Lett.</i> , 2000, 10: 1467-1470.
	C19	Shih, et al., "Design and Synthesis of the Novel and Orally Active Dual NK ₁ and NK ₂ Antagonist Sch 205528", <i>Abstract, Books of Abstracts. - Am. Chem. Soc.</i> , 2000, MEDI-129.
	C20	Bernstein, et al., "Discovery of Novel, Orally Active Dual NK ₁ /NK ₂ Antagonists", <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11: 2769-2773.
	C21	Ting, et al., "Identification of a Novel 1'-[5-((3,5-dichlorobenzoyl)methylamino)-3-(3,4-dichlorophenyl)-4-methoxymino)pentyl]-2-oxo-(1,4'-bipiperidine) as a Dual NK ₁ /NK ₂ Antagonist", <i>Bioorg. Med. Chem. Lett.</i> , 2002, 12: 2125-2128.
	C22	Nishi, T., "Synthetic Studies for the Novel Morpholine and Oxazolidine-Based Tachykinin Receptor Antagonists", <i>Yuki Gosei Kagaku Kyokaishi</i> , 2002, 60(7):657-667.
	C23	Ford-Hutchinson, et al., "Novel Therapeutic Strategies for the Treatment of Human Bronchial Asthma", <i>Drug News Perspect.</i> , 1992, 5(9):542-549.
	C24	Geppetti, et al., "New Aspects on the Role of Kinins in Nneurogenic Inflammation", <i>Can. J. Physiol. Pharmacol.</i> , 1995, 73:843-847.
	C25	Advenier, et al., "The Role of Tachykinin Receptor Antagonists in the Prevention of Bronchial Hyperresponsiveness, Airway Inflammation and Cough", <i>Eur. Respir. J.</i> , 1997, 10(8):1892-1906.
	C26	Chapman, et al., "Tachykinins in the Lung", <i>Drug News Perspect.</i> , 1998, 11(8):480-489.
	C27	Murai, et al., "Effects of FK224, a Novel Compound NK ₁ and NK ₂ Receptor Antagonist, on Airway Constriction and Airway Edema Induced by Neurokinins and Sensory Nerve Stimulation in Guinea Pigs", <i>J. Pharmacol. Exp. Ther.</i> , 1992, 262(1):403-408.
	C28	Joos, et al., "The effect of Inhaled FK224, a Tachykinin NK ₁ and NK ₂ Receptor Antagonist, on Neurokinin A-Induced Bronchoconstriction in Asthmatics", <i>Am. J. Respir. Crit. Care Med.</i> , 1996, 153(6):1781-1784.
	C29	Joos, et al., "Tachykinin Receptors Antagonists: Potential in Airways Diseases", <i>Curr. Opin. Pharmacol.</i> , 2001, 1(3):235-241.
	C30	Gerspacher, et al., "Dual Neurokinin NK ₁ /NK ₂ Antagonists: N-[(R, R)-(E)-1-arylmethyl-3-(2-oxo-azepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzoyl-N-arylmethyl-N'-methylhydrazinol]-N-[(R)-2-oxo-azepan-3-yl]propionamides", <i>Bioorg. Med. Chem. Lett.</i> , 2001, 11(23):3081-3084.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered
-----------------------	--	--------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.